Physician profile
Douglas Taylor
NPI 1093735284
$4,547.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $821 · 2021: $1,244 · 2022: $890 · 2023: $722 · 2024: $15.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,415.67 | 2019-2023 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $922.86 | 2019-2024 | Sunlenca |
| Merck Sharp & Dohme LLC | $429.62 | 2019-2023 | Delstrigo, Pifeltro |
| Janssen Biotech, INC. | $344.08 | 2019-2022 | |
| Abbvie INC. | $338.15 | 2019-2023 | Mavyret |
| Emd Serono, INC. | $311.11 | 2019-2023 | Serostim |
| Janssen Products, Lp | $213.99 | 2020-2021 | |
| Theratechnologies INC. | $162.82 | 2019-2021 | |
| Novo Nordisk INC | $145.22 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $130.03 | 2021-2022 | |
| Napo Pharmaceuticals INC | $59.25 | 2019-2023 | Mytesi |
| Pfizer INC. | $29.50 | 2023 | |
| Paratek Pharmaceuticals, INC. | $15.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2020 | |
| Lilly USA, LLC | $14.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.